The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT

31.07.25 14:45 Uhr

Werte in diesem Artikel

NEW YORK, July 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).

The Gross Law Firm (PRNewsfoto/The Gross Law Firm)

Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=158789&from=4

CLASS PERIOD: June 22, 2023 to June 24, 2025

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.

DEADLINE: August 25, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=158789&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SRPT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 25, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-reminds-shareholders-of-a-lead-plaintiff-deadline-of-august-25-2025-in-sarepta-therapeutics-inc-lawsuit--srpt-302518146.html

SOURCE The Gross Law Firm

In eigener Sache

Übrigens: Sarepta Therapeutics und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Sarepta Therapeutics

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Sarepta Therapeutics

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Sarepta Therapeutics Inc.

Wer­bung

Analysen zu Sarepta Therapeutics Inc.

DatumRatingAnalyst
21.08.2019Sarepta Therapeutics BuyNeedham & Company, LLC
01.10.2018Sarepta Therapeutics OverweightCantor Fitzgerald
21.06.2018Sarepta Therapeutics OutperformRobert W. Baird & Co. Incorporated
20.06.2018Sarepta Therapeutics BuyNeedham & Company, LLC
19.06.2018Sarepta Therapeutics BuyH.C. Wainwright & Co.
DatumRatingAnalyst
21.08.2019Sarepta Therapeutics BuyNeedham & Company, LLC
01.10.2018Sarepta Therapeutics OverweightCantor Fitzgerald
21.06.2018Sarepta Therapeutics OutperformRobert W. Baird & Co. Incorporated
20.06.2018Sarepta Therapeutics BuyNeedham & Company, LLC
19.06.2018Sarepta Therapeutics BuyH.C. Wainwright & Co.
DatumRatingAnalyst
26.04.2016Sarepta Therapeutics Sector PerformRBC Capital Markets
22.04.2016Sarepta Therapeutics Sector PerformRBC Capital Markets
20.05.2015Sarepta Therapeutics Sector PerformRBC Capital Markets
23.01.2015Sarepta Therapeutics Sector PerformRBC Capital Markets
28.10.2014Sarepta Therapeutics NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
26.04.2016Sarepta Therapeutics ReduceSunTrust Robinson Humphrey, Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sarepta Therapeutics Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen